ACP
HARP

Acuta Capital Partners’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Acuta Capital Partners’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49,750
Closed -$2.47M – 52
2022
Q1 		$2.47M Buy
+49,750
New +$2.58M 1.16% 26

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acuta Capital Partners's HARP Position: Q2 2022 in Review

Acuta Capital Partners sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 49,750 shares — an estimated $2.47M sold.

Acuta Capital Partners first reported a position in HARP in Q1 2022 and held it in 1 quarter. The position peaked at $2.47M in Q1 2022. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Acuta Capital Partners reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 49,750 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $2.47M.
  • Acuta Capital Partners first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Acuta Capital Partners's Harpoon Therapeutics, Inc. Common Stock position peaked at $2.47M in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.